Atogepant for the Preventive Treatment of Migraine von Ailani, Jessica, Lipton, Richard B, Goadsby, Peter J, Guo, Hua, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Volltext

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial von Ailani, Jessica, Lipton, Richard B., Hutchinson, Susan, Knievel, Kerry, Lu, Kaifeng, Butler, Matthew, Yu, Sung Yun, Finnegan, Michelle, Severt, Lawrence, Trugman, Joel M.

Volltext

Atogepant: Mechanism of action, clinical and translational science von Boinpally, Ramesh, Shebley, Mohamad, Trugman, Joel M.

Volltext

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial von Lipton, Richard B, Dodick, David W, Ailani, Jessica, Lu, Kaifeng, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M

Volltext

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial von Goadsby, Peter J, Dodick, David W, Ailani, Jessica, Trugman, Joel M, Finnegan, Michelle, Lu, Kaifeng, Szegedi, Armin

Volltext

Ubrogepant for the Treatment of Migraine von Dodick, David W, Lipton, Richard B, Ailani, Jessica, Lu, Kaifeng, Finnegan, Michelle, Trugman, Joel M, Szegedi, Armin

Volltext

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial von Pozo-Rosich, Patricia, Ailani, Jessica, Ashina, Messoud, Goadsby, Peter J, Lipton, Richard B, Reuter, Uwe, Guo, Hua, Schwefel, Brittany, Lu, Kaifeng, Boinpally, Ramesh, Miceli, Rosa, De Abreu Ferreira, Rosa, McCusker, Emily, Yu, Sung Yun, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Volltext

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies von Boinpally, Ramesh, Depré, Marleen, Van Lancker, Griet, Dockendorf, Marissa F, Bondiskey, Phung, Denef, Jean-Francois, Reynders, Tom, Matthews, Catherine Zhou, Min, K Chris, Xu, Jialin, Trugman, Joel M, de Hoon, Jan

Volltext

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, p... von Tassorelli, Cristina, Nagy, Krisztián, Pozo-Rosich, Patricia, Lanteri-Minet, Michel, Sacco, Sara, Nežádal, Tomáš, Guo, Hua, De Abreu Ferreira, Rosa, Forero, Giovanna, Trugman, Joel M

Volltext

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial von Schwedt, Todd J, Lipton, Richard B, Ailani, Jessica, Silberstein, Stephen D, Tassorelli, Cristina, Guo, Hua, Lu, Kaifeng, Dabruzzo, Brett, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Volltext

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial von Ashina, Messoud, Tepper, Stewart J., Reuter, Uwe, Blumenfeld, Andrew M., Hutchinson, Susan, Xia, Jing, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M.

Volltext

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial von Goadsby, Peter J, Friedman, Deborah I, Holle-Lee, Dagny, Demarquay, Genevieve, Ashina, Sait, Sakai, Fumihiko, Neel, Brian, Gandhi, Pranav, Dabruzzo, Brett, Smith, Jonathan H, Liu, Yingyi, Trugman, Joel M

Volltext

Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA von Dodick, David W, Goadsby, Peter J, Schwedt, Todd J, Lipton, Richard B, Liu, Chengcheng, Lu, Kaifeng, Yu, Sung Yun, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Volltext

Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis von MacGregor, E. Anne, Hutchinson, Susan, Lai, Hongxin, Dabruzzo, Brett, Yu, Sung Yun, Trugman, Joel M., Ailani, Jessica

Volltext

Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials von Iaconangelo, Charlie J., Serrano, Daniel, Adams, Aubrey Manack, Trugman, Joel M., Lipton, Richard B.

Volltext

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults von Goadsby, Peter J, Tepper, Stewart J, Watkins, Paul B, Ayele, Girma, Miceli, Rosa, Butler, Matthew, Severt, Lawrence, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M, Jakate, Abhijeet

Volltext

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial von Klein, Brad C, Miceli, Rosa, Severt, Lawrence, McAllister, Peter, Mechtler, Laszlo, McVige, Jennifer, Diamond, Merle, Marmura, Michael J, Guo, Hua, Finnegan, Michelle, Trugman, Joel M

Volltext

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine von Blumenfeld, Andrew M., Boinpally, Ramesh, De Abreu Ferreira, Rosa, Trugman, Joel M., Dabruzzo, Brett, Ailani, Jessica, Lipton, Richard B.

Volltext

Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet von Boinpally, Ramesh R., Trugman, Joel M.

Volltext

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II von Dodick, David W., Lipton, Richard B., Ailani, Jessica, Halker Singh, Rashmi B., Shewale, Anand R., Zhao, Sihui, Trugman, Joel M., Yu, Sung Yun, Viswanathan, Hema N.

Volltext